The surge of clinical approvals in CKD and unprecedented use of surrogate endpoints in rare kidney diseases have catalysed a new era of complimentary therapies and precision medicine in drug development for kidney disease. As investment floods into rare disorders and cell and gene therapy reimagine regenerative medicine, there has never been more stakeholders in CKD.

Uniting industry experts dedicated to accelerating the frontier of pioneering research beyond the new standard of care and breaking new ground with redefined patient inclusion criteria, the 5^th Chronic Kidney Disease Drug Development Summit was the definitive industry forum sharing cross-industry insight to bring effective therapies to patients faster.

From executing deep characterization of disease etiology to stratify patients based on molecular features of disease to driving a culture of clinical study in nephrology to efficiently recruit relevant patient populations, industry experts from AstraZeneca, Goldfinch Bio, Bayer, Boehringer Ingelheim, Travere, Novo Nordisk, the FDA, Sanofi, Johnson & Johnson and many more navigated the translational gap and accelerated the pathway to clinical success.